Grab it!

Optimised MTX management from the market leader1

WELCOME TO OUR SPECIALIST PLATFORM

explore more

As market leader1, our goal is to continuously optimise the management of treatment with MTX – and in doing so to achieve further improvements in the quality of life for patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, psoriasis vulgaris and Crohn’s disease.

On our specialist platform, healthcare professionals can find study results, the latest information from guidelines along with other scientific background information concerning the use of methotrexate (MTX) to treat autoimmune diseases – as well as the use of our simplified metoject® PEN: GRAB IT!

SIMPLIFIED PEN

As market leader in the field of subcutaneous methotrexate1, medac always tries to provide patients with the best possible product. We are therefore very happy to introduce the simplified metoject® PEN, which represents the next step in the evolution of our pre-filled methotrexate PEN.  

ACTIVE SUBSTANCE MTX 

MTX was initially designed to inhibit DNA and RNA synthesis and thus the proliferation of malignant cells – at dosages measured in grams. Meanwhile, further mechanisms of action are associated with MTX that may contribute to the anti-inflammatory actions of methotrexate in the treatment of RA. MTX may regulate, both directly and indirectly, the function of nearly every cell type involved in inflammation. 

SC VS ORAL STUDIES

In the treatment of autoimmune diseases like rheumatoid arthritis and psoriasis, study results speak for the superiority of subcutaneous MTX application when compared to oral MTX with regard to efficacy, bioavailability, tolerability and therapy continuity. 

GUIDELINES

Today, MTX is one of the basic medications for moderate to severe psoriasis, severe psoriatic arthritis or mild to moderate Crohn’s disease – and is the gold standard in the treatment of  active rheumatoid arthritis. It is also the preferred combination partner with biologics and small molecules in the treatment of rheumatoid arthritis. The use of MTX in these chronic inflammatory autoimmune diseases is considered in numerous international treatment guidelines issued by the relevant professional societies.

EULAR MEDIA PAGE

This is our page with exciting highlights from the EULAR. Here, you can watch our symposium or listen to our informative podcast. You can also find expert interviews on the treatment of RA with a focus on SC MTX. 

CARE AND CONVERSATION

The diagnosis of a chronic inflammatory autoimmune disease means a major break in life for many affected persons and can cause a great deal of worry and concern.  Regarding the expected adherence to treatment, it is important to clarify open questions in a way that can be easily understood. Counselling is needed that responds empathetically to the concerns of those affected. 

Self-injection if patients are using the previous MTX PEN

Related Content

Pre-filled syringe for MTX injection

The MTX autoinjector metoject® PEN

1 IQVIA MIDAS Quarterly Sales Audit from Q2 2019 to Q4 2022